Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Postmastectomy locoregional recurrence and recurrence-free survival in breast cancer patients | Kheradmand et al. World Journal of Surgical Oncology 2010 8 30 http content 8 1 30 RESEARCH WORLD JOURNAL OF SURGICAL ONCOLOGY Open Access Postmastectomy locoregional recurrence and recurrence-free survival in breast cancer patients Ali Arab Kheradmand1 Neda Ranjbarnovin 2 and Zahra Khazaeipour3 Abstract Background One essential outcome after breast cancer treatment is recurrence of the disease. Treatment decision is based on assessment of prognostic factors of breast cancer recurrence. This study was to investigate the prognostic factors for postmastectomy locoregional recurrence LRR and survival in those patients. Methods 114 patients undergoing mastectomy and adjuvant radiotherapy in Cancer Institute of Tehran University of Medical Sciences were retrospectively reviewed between 1996 and 2008. All cases were followed up after initial treatment of patients with breast cancer via regular visit annually for discovering the LRR. Cumulative recurrence free survival RFS was determined using the Kaplan-Meier method with univariate comparisons between groups through the log-rank test. The Cox proportional hazards model was used for multivariate analysis. Result The median follow up time was 84 months range 2-140 . Twenty-three patients developed LRR. Cumulative RFS rate at years and 5 years were 86 95 CI 81-91 and 95 CI 77-87 respectively. Mean RFS was months range - months 95 CI . At univariate and multivariate analysis factors had not any influence on the LRR. Conclusion Despite use of adjuvant therapies during the study we found a LRR rate after mastectomy of . Therefore for patients with LRR without evidence of distant disease aggressive multimodality therapy is warranted. Background Breast cancer is the main cause of death that affects women worldwide 1 . Women who have been diagnosed with breast cancer and have completed initial treatments remain at risk for recurrent cancer 2 3 . Surgery combined with .
